IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Jan-2025
Active ingredients
durvalumab
Proposed indication
IMFINZI (durvalumab) is for the treatment of muscle invasive bladder cancer.
Application type
C (new indication)
Publication date
Jan-2025